2 results match your criteria: "Pharmacogenomic Center[Affiliation]"
Potential clinical biomarkers in rheumatoid arthritis with an omic approach.
Auto Immun Highlights
May 2021
Pharmacogenomic Center, Medellín, Colombia.
Article Synopsis
- The objective of the study was to identify suitable therapeutic options for rheumatoid arthritis patients based on disease phase and omics biological markers.
- A systematic review of articles from PubMed/Medline revealed 196 potential clinical biomarkers, categorized into various omics fields (like genomics and proteomics), which assist in treatment decisions.
- The findings concluded that new biomarkers, particularly omics, enhance the ability of physicians to select effective therapies for rheumatoid arthritis by evaluating patients at molecular and cellular levels.
Assessing Splanchnic Compartment Using Portal Venous Doppler and Impact of Adding It to the EVEREST Score for Risk Assessment in Heart Failure.
CJC Open
September 2020
Department of Medicine of the Montreal Heart Institute, Université de Montréal, Montreal, Québec, Canada.
Background: The Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) score has proven useful for risk prediction in acute decompensated heart failure (ADHF). However, this score does not include the characterization of the splanchnic compartment, which has been involved in worsening heart failure. Refining this score by integrating an assessment of the splanchnic compartment would allow for a better risk assessment.
View Article and Find Full Text PDF